252 related articles for article (PubMed ID: 24573676)
41. Timeless-Tipin interactions with MCM and RPA mediate DNA replication stress response.
Prorok P; Wolf E; Cardoso MC
Front Cell Dev Biol; 2024; 12():1346534. PubMed ID: 38487270
[TBL] [Abstract][Full Text] [Related]
42. Phosphorylation of BLM, dissociation from topoisomerase IIIalpha, and colocalization with gamma-H2AX after topoisomerase I-induced replication damage.
Rao VA; Fan AM; Meng L; Doe CF; North PS; Hickson ID; Pommier Y
Mol Cell Biol; 2005 Oct; 25(20):8925-37. PubMed ID: 16199871
[TBL] [Abstract][Full Text] [Related]
43. Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes.
Furuta T; Takemura H; Liao ZY; Aune GJ; Redon C; Sedelnikova OA; Pilch DR; Rogakou EP; Celeste A; Chen HT; Nussenzweig A; Aladjem MI; Bonner WM; Pommier Y
J Biol Chem; 2003 May; 278(22):20303-12. PubMed ID: 12660252
[TBL] [Abstract][Full Text] [Related]
44. Mammalian TIMELESS and Tipin are evolutionarily conserved replication fork-associated factors.
Gotter AL; Suppa C; Emanuel BS
J Mol Biol; 2007 Feb; 366(1):36-52. PubMed ID: 17141802
[TBL] [Abstract][Full Text] [Related]
45. Activity of a novel camptothecin analogue, homocamptothecin, in camptothecin-resistant cell lines with topoisomerase I alterations.
Urasaki Y; Takebayashi Y; Pommier Y
Cancer Res; 2000 Dec; 60(23):6577-80. PubMed ID: 11118036
[TBL] [Abstract][Full Text] [Related]
46. Chromatin remodeler ALC1 prevents replication-fork collapse by slowing fork progression.
Ooka M; Abe T; Cho K; Koike K; Takeda S; Hirota K
PLoS One; 2018; 13(2):e0192421. PubMed ID: 29408941
[TBL] [Abstract][Full Text] [Related]
47. Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites.
Pommier Y; Kohlhagen G; Kohn KW; Leteurtre F; Wani MC; Wall ME
Proc Natl Acad Sci U S A; 1995 Sep; 92(19):8861-5. PubMed ID: 7568032
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of topoisomerase I cleavage activity by thiol-reactive compounds: importance of vicinal cysteines 504 and 505.
Montaudon D; Palle K; Rivory LP; Robert J; Douat-Casassus C; Quideau S; Bjornsti MA; Pourquier P
J Biol Chem; 2007 May; 282(19):14403-12. PubMed ID: 17355975
[TBL] [Abstract][Full Text] [Related]
49. Topoisomerase IIβ deficiency enhances camptothecin-induced apoptosis.
Lin RK; Ho CW; Liu LF; Lyu YL
J Biol Chem; 2013 Mar; 288(10):7182-92. PubMed ID: 23344961
[TBL] [Abstract][Full Text] [Related]
50. Topoisomerase I inhibitors: Challenges, progress and the road ahead.
Talukdar A; Kundu B; Sarkar D; Goon S; Mondal MA
Eur J Med Chem; 2022 Jun; 236():114304. PubMed ID: 35413618
[TBL] [Abstract][Full Text] [Related]
51. Modulation in kinetics of lactone ring hydrolysis of camptothecins upon interaction with topoisomerase I cleavage sites on DNA.
Chourpa I; Riou JF; Millot JM; Pommier Y; Manfait M
Biochemistry; 1998 May; 37(20):7284-91. PubMed ID: 9585542
[TBL] [Abstract][Full Text] [Related]
52. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site.
Urasaki Y; Laco G; Takebayashi Y; Bailly C; Kohlhagen G; Pommier Y
Cancer Res; 2001 Jan; 61(2):504-8. PubMed ID: 11212241
[TBL] [Abstract][Full Text] [Related]
53. Synthesis and biological activities of two camptothecin derivatives against Spodoptera exigua.
Yang F; Wang L; Zhang L; Zhang Y; Mao L; Jiang H
Sci Rep; 2019 Dec; 9(1):18067. PubMed ID: 31792297
[TBL] [Abstract][Full Text] [Related]
54. Cellular processing determinants for the activation of damage signals in response to topoisomerase I-linked DNA breakage.
Huang TH; Chen HC; Chou SM; Yang YC; Fan JR; Li TK
Cell Res; 2010 Sep; 20(9):1060-75. PubMed ID: 20603643
[TBL] [Abstract][Full Text] [Related]
55. Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel.
Maede Y; Shimizu H; Fukushima T; Kogame T; Nakamura T; Miki T; Takeda S; Pommier Y; Murai J
Mol Cancer Ther; 2014 Jan; 13(1):214-20. PubMed ID: 24130054
[TBL] [Abstract][Full Text] [Related]
56. Genome-destabilizing effects associated with top1 loss or accumulation of top1 cleavage complexes in yeast.
Andersen SL; Sloan RS; Petes TD; Jinks-Robertson S
PLoS Genet; 2015 Apr; 11(4):e1005098. PubMed ID: 25830313
[TBL] [Abstract][Full Text] [Related]
57. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system.
Tsao YP; Russo A; Nyamuswa G; Silber R; Liu LF
Cancer Res; 1993 Dec; 53(24):5908-14. PubMed ID: 8261402
[TBL] [Abstract][Full Text] [Related]
58. Camptothecin, a specific inhibitor of type I DNA topoisomerase, induces DNA breakage at replication forks.
Avemann K; Knippers R; Koller T; Sogo JM
Mol Cell Biol; 1988 Aug; 8(8):3026-34. PubMed ID: 2850477
[TBL] [Abstract][Full Text] [Related]
59. The bromodomain and extra-terminal domain inhibitor JQ1 synergistically sensitizes human colorectal cancer cells to topoisomerase I inhibitors through repression of Mre11-mediated DNA repair pathway.
Lei L; Xie X; He L; Chen K; Lv Z; Zhou B; Li Y; Hu W; Zhou Z
Invest New Drugs; 2021 Apr; 39(2):362-376. PubMed ID: 32981006
[TBL] [Abstract][Full Text] [Related]
60. Nascent DNA Proteomics Reveals a Chromatin Remodeler Required for Topoisomerase I Loading at Replication Forks.
Ribeyre C; Zellweger R; Chauvin M; Bec N; Larroque C; Lopes M; Constantinou A
Cell Rep; 2016 Apr; 15(2):300-9. PubMed ID: 27050524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
